PEG-Intron Related Clinical Trials
Three Regimens of PEG-Intron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548AM2)(COMPLETED) [Completed]
Peg-Ifn Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471AM1)(COMPLETED) [Completed]
Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538AM1)(COMPLETED) [Completed]
Extended Treatment With PEG-Intron and Rebetol in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685AM3) [Active, not recruiting]
A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma [Recruiting]
PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML [Active, not recruiting]
Peg-Intron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (Study P04498) [Active, not recruiting]
Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209) [Recruiting]
Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2) [Active, not recruiting]
The Effects of PEG-Intron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833AM2) [Active, not recruiting]
Study of Long-Term Peg Intron Vs. Colchicine in Non-Responders. [Active, not recruiting]
A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms [Recruiting]
Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584) [Recruiting]
Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With Chronic Hepatitis C [Active, not recruiting]
High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831AM1) [Active, not recruiting]
Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine [Recruiting]
Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients [Recruiting]
Phase III PEG-Intron in HIV-Infected Patients (Study P00738)(COMPLETED) [Completed]
Study of Vaniprevir Plus PegIntron�/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044 AM1) [Recruiting]
Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569AM2)(COMPLETED) [Completed]
Study of PEG-Intron for Plexiform Neurofibromas [Recruiting]
PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron [Terminated]
Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients [Recruiting]
Pegintron to Treat Plexiform Neurofibromas in Children and Young Adults [Recruiting]
Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED) [Terminated]
PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer [Recruiting]
Three-Year Follow-up of Subjects After Administration of Boceprevir for the Treatment of Chronic Hepatitis C (Study P05063) [Enrolling by invitation]
Trial of Peg-Interferon Plus Epoetin-Alfa for Treatment of Chronic Hepatitis C Virus Infection [Completed]
Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma [Recruiting]
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma [Recruiting]
Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders [Terminated]
SCH 503034 Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659)(COMPLETED) [Completed]
Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)(COMPLETED) [Completed]
Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3) [Active, not recruiting]
Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045 AM2) [Recruiting]
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) [Active, not recruiting]
Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144) [Active, not recruiting]
Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With PegIntron (Peginterferon α-2b) and Rebetol (Ribavirin) in the Czech Republic (Study P04588) [Recruiting]
A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects [Active, not recruiting]
ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (Study P05632AM2) [Recruiting]
Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469) [Active, not recruiting]
5-Aza-2-Deoxycitidine With Pegylated Interferon-Alfa 2B: A Phase I Study With Molecular Correlates [Recruiting]
Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children [Active, not recruiting]
Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D co-Infection (Study P04603AM3) [Active, not recruiting]
PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370AM2)(COMPLETED) [Completed]
Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043 AM1) [Recruiting]
Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690) [Recruiting]
Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors [Completed]
PegIntron Injection Surveillance Plan (Study P04123) [Recruiting]
Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Patients With Acute Hepatitis C (Study P03552) [Recruiting]
CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma [Active, not recruiting]
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and Peginterferon Alfa-2b [PEG-INTRON(R)] [Recruiting]
Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM1) [Recruiting]
Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON) [Terminated]
5 Year Long-term Follow up in Pediatric Subjects Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt2) [Recruiting]
Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655 AM1) [Not yet recruiting]
Efficacy of Peginterferon Alfa-2b (SCH 54031) vs Glycyrrhizin in Interferon(IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (Study P04773) [Recruiting]
The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections [Completed]
PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer [Active, not recruiting]
PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy [Completed]
Zidovudine, Interferon Alfa-2b, and PEG-Interferon Alfa-2b in Treating Patients With Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia/Lymphoma [Recruiting]
Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269) [Recruiting]
PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (Study P05170) [Recruiting]
A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C [Recruiting]
Safety and Effectiveness of PEG-Intron in HIV-Infected Patients [Completed]
Influence of Marker of Insulin Resistance Upon HCV Treatment Responses to PEG Intron and Rebetol Therapy
Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection
Sodium Stibogluconate and Interferon Alfa-2b Followed By Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Advanced Melanoma or Other Cancer [Not yet recruiting]
Comparison of PEG-Intron and Two Different Doses of Ribavirin for the Treatment of Chronic Hepatitis C In Treatment Naïve Subjects
PEG-Interferon Alfa-2b and Ultraviolet Light Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Mycosis Fungoides/Sezary Syndrome [Recruiting]
Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM1) [Recruiting]
Effects of Low-Dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371) [Withdrawn]
An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494) [Not yet recruiting]
PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer [Active, not recruiting]
PEG-Interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery [Completed]
Zidovudine Levels in HIV Infected Patients Being Treated for HCV [Active, not recruiting]
PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent High-Grade Gliomas [Recruiting]
PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma
Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer [Recruiting]
PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101) [Recruiting]
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma [Recruiting]
PEG-IFN Plus Ribavirin Combination Therapy for Older Patients [Recruiting]
Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED) [Terminated]
Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma [Withdrawn]
Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (Study P05484) [Recruiting]
Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors
The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin [Recruiting]
Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C [Recruiting]
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy. [Recruiting]
Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia [Recruiting]
Study of SCH 54031 in Surgically Resectable Squamous Cell Tumors of the Head and Neck [Terminated]
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM2) [Recruiting]
Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016) [Recruiting]
Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4 [Recruiting]
Pegylated Interferon Alpha-2b Monotherapy Versus Combination With Entecavir in HBeAg-negative Chronic Hepatitis B [Recruiting]
PegIntron vs IntronA in CMAJCC Stage II (EADO 2001/CMII Trial). [Recruiting]
Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181) [Recruiting]
Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C [Recruiting]
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients [Recruiting]
Efficacy of Pegetron® Redipenâ„¢ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (Study P04423) [Recruiting]
|
